ABBV
Another green light, but not the finish line
AbbVie says the European Medicines Agency’s CHMP has adopted a positive opinion recommending approval of upadacitinib, sold as RINVOQ, for adults and adolescents with non-segmental vitiligo. In plain English: Europe just got one step closer to giving AbbVie another new use for a drug that’s already become a pretty important revenue machine.
Why vitiligo matters
Vitiligo isn’t just a cosmetic footnote. It’s a chronic autoimmune disease, and AbbVie is pitching RINVOQ as the first systemic medication for patients with the non-segmental form. That matters because the market likes drugs that keep finding new reasons to exist. More indications = more ways to keep the growth story alive after the original hype cycle has faded.
The data pitch
AbbVie says the positive opinion is backed by Phase 3 Viti-Up studies, where upadacitinib hit both co-primary endpoints:
- at least 50% improvement in total body repigmentation at week 48
- at least 75% improvement in facial repigmentation at week 48
That’s the kind of sentence that sounds like it was assembled by a committee of scientists and lawyers, but the takeaway is simple: the drug showed enough skin-deep progress to convince regulators it deserves a closer look.
What happens next
A CHMP opinion isn’t the final curtain call. It’s more like the trailer before the movie. The European Commission still has to make the actual approval decision, but this is a meaningful step in that direction.
Big picture: for AbbVie, every new label extension is another brick in the wall supporting RINVOQ’s long-term value story. And in biotech-land, those bricks can be worth a lot.